Header Logo

Connection

Lynn Morris to Antibodies, Viral

This is a "connection" page, showing publications Lynn Morris has written about Antibodies, Viral.
Connection Strength

0,926
  1. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol. 2007 Oct; 81(19):10769-76.
    View in: PubMed
    Score: 0,244
  2. Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern. Sci Rep. 2025 Feb 14; 15(1):5549.
    View in: PubMed
    Score: 0,206
  3. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
    View in: PubMed
    Score: 0,158
  4. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity. 2014 Dec 18; 41(6):909-18.
    View in: PubMed
    Score: 0,101
  5. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 2009 Aug; 15(8):866-70.
    View in: PubMed
    Score: 0,070
  6. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology. 2007 Nov 10; 368(1):172-81.
    View in: PubMed
    Score: 0,061
  7. Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa. Epidemiol Infect. 2003 Dec; 131(3):1125-9.
    View in: PubMed
    Score: 0,047
  8. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 04; 27(4):622-625.
    View in: PubMed
    Score: 0,039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.